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In Brief
It is generally believed that
neurodegeneration is accompanied by
BBB dysfunction, potentially increasing
drug bioavailability in the CNS. Bien-Ly et
al. report that AD mouse models lack
widespread BBB disruption and display
restricted passive permeability to
therapeutic antibodies.
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The blood-brain barrier (BBB) limits brain uptake of
therapeutic antibodies. It is believed that the BBB
is disrupted in Alzheimer’s disease (AD), potentially
increasing drug permeability de facto. Here we
compared active versus passive brain uptake of sys-
temically dosed antibodies (anti-transferrin receptor
[TfR] bispecific versus control antibody) in mouse
models of AD. We first confirmed BBB disruption in
a mouse model of multiple sclerosis as a positive
control. Importantly, we found that BBB permeability
was vastly spared in mouse models of AD, including
PS2-APP, Tau transgenics, and APOE4 knockin
mice. Brain levels of TfR in mouse models or in hu-
man cases of AD resembled controls, suggesting
target engagement of TfR bispecific is not limited.
Furthermore, infarcts from human AD brain showed
similar occurrences compared to age-matched con-
trols. These results question thewidely held view that
the BBB is largely disrupted in AD, raising concern
about assumptions of drug permeability in disease.
INTRODUCTION
The extent of BBB impairment in neurodegenerative disease and
how it affects the bioavailability of therapeutics remains unclear.
Focusing on AD, the assessment of BBB disruption has been
described using various methods (Nicolakakis and Hamel,
2011; Erickson and Banks, 2013). Studies in AD mouse models
suggest that the greatest determinant of altered cerebrovascular
function and BBB disruption is vascular amyloid deposition (Han
et al., 2008; Maier et al., 2014), which may lead to localized tran-
sient BBB disruption. In fact, cerebrovascular lesions were more
frequently observed in post-mortem AD cases with coincidentcerebrovascular amyloid angiopathy (De Reuck, 2012). How-
ever, BBB impairments may exist in non-amyloid-depositing
AD models such as APOE4 mice (Bell et al., 2012) or mutant
human tau transgenic mice (Blair et al., 2015).
We investigated the extent of BBB breakdown across multiple
AD mouse models, focusing on determining brain penetrance of
therapeutic antibodies. We used anti-TfR/BACE1 versus anti-
BACE1 and control antibody to compare active brain uptake
versus passive IgG leakage (Yu et al., 2011; Couch et al.,
2013). We first assessed a model of multiple sclerosis with re-
ported BBB and blood-spinal cord barrier (BSCB) disruption
(Bennett et al., 2010) and observed extensive barrier perme-
ability to IgG. In contrast, minimal BBB disruption was detected
in PS2-APP transgenic mice, human Tau P301L and P301S
mutant mice, and mice lacking APOE or expressing human
APOE4. We also found that TfR levels were unaltered in these
AD models and in human AD post-mortem samples compared
to controls, suggesting brain uptake of TfR-based therapeutics
may be unimpaired. These findings, combined with an extensive
analysis of brain infarcts in age-matched control and AD sam-
ples, indicate a lack of widespread BBB disruption in AD and
further support the need for an enhanced BBB-crossing thera-
peutic delivery platform.RESULTS
Detection of BBB Antibody Permeability in EAE-Induced
Mice
To establish a BBB antibody permeability assessment paradigm,
we utilized a disease model with BSCB disruption and evidence
of BBB leakage. Mice were induced to develop experimental
autoimmune encephalomyelitis (EAE), a preclinical model ofmul-
tiple sclerosis (MS). At peak disease onset (15 days post-inocu-
lation), naive and EAE-induced mice were intravenously (i.v.) in-
jected with 25 mg/kg of control IgG (Con IgG), anti-BACE1, or
anti-TfRD/BACE1 (Figure 1A). We reasoned that BBB disruption
would allow passive entry of significantly more antibody into theNeuron 88, 289–297, October 21, 2015 ª2015 Elsevier Inc. 289
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Figure 1. Robust Leakage of Injected and Endogenous IgG into Brain and Spinal Cord in EAE Mice
(A) Schematic of BBB permeability assay. Control (naive) and disease (EAE-induced) mice were injected with 25 mg/kg of Control (Con) IgG, anti-TfRD/BACE1
bispecific antibody, or anti-BACE1 bivalent antibody at day 15 of disease progression (peak disease onset) and analyzed at 24 hr for antibody levels in cortex
(includes hippocampus), cerebellum, and spinal cord.
(B–D) Human IgG concentrations were measured by ELISA.
(E) Cortical lysates were analyzed by western blot for endogenous mouse IgG. n = naive, E(number) = EAE-induced (clinical score, indicates severity of onset).
HC = heavy chain, LC = light chain of IgG.
(F–H) Quantification of blots for levels of mouse IgG HC in cortex (F), cerebellum (G), and spinal cord (H) lysates. All raw values were normalized to actin as a
loading control and to naive animals within each group. n = 4–5 per group. Note some poorly perfused mice were excluded from HC IgG quantification (denoted
by bold, italicized labels) based on visual inspection after perfusion. Data points represent individual mice; graphs show mean ± standard error of mean (SEM).
**p < 0.01 and ***p < 0.001, naive versus EAE by Student’s t test. kDa, kilodaltons. See also Figure S1.
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CNS relative to naive controls, regardless of enhanced BBB
crossing via receptor-mediated transcytosis (anti-TfRD/BACE1)
or not (Con IgG and anti-BACE1). Because we have previously
shown degradation of TfR (and bispecific antibodies against
TfR) in brain endothelial cells is mediated by antibody affinity
(Bien-Ly et al., 2014), we used low-affinity TfRD bispecific in
our studies. This approach also allowed us to determine whether
active brain uptake of anti-TfRD/BACE1 (Yu et al., 2011; Couch
et al., 2013) was similar to or exceeded the passive entry of
Con IgG or anti-BACE1 due to BBB disruption. All antibodies
were on a human IgG1 backbone, allowing for sensitive mea-
surements of drug concentrations in mouse brain by a human
IgG Fc-specific ELISA. Dosing with anti-BACE1 or anti-TfRD/
BACE1 also enabled assessment of target engagement (i.e.,
BACE1 inhibition) by measuring amyloid-b (Ab) concentrations
from brain lysates. After 24 hr, we extensively perfused the
mice to remove circulating vascular IgG and measured antibody
levels in cortex (includes hippocampus), cerebellum, and spinal
cord lysates. We observed 3-fold more Con IgG and anti-BACE1
in the cortex of EAE-induced animals compared to naivemice, 5-
to 10-fold more in cerebellum, and up to 80-fold more antibody
in diseased spinal cord (Figures 1B–1D). Importantly, levels of
anti-TfRD/BACE1 were not significantly different between EAE
and naive mice in all regions, were 10-fold higher compared to
Con IgG in naive mice, and were 2- to 3-fold higher than levels
of Con IgG in the cortex and cerebellum of EAE mice. These
findings demonstrate that TfR bispecific antibodies penetrate
the BBB and actively access the cortex to a greater extent
than non-targeting IgGs, regardless of disease state or subse-
quent barrier disruption. Spinal cord displayed more Con IgG
and anti-BACE1 in EAE mice than TfR bispecific, suggesting
greater barrier dysfunction and antibody penetrance in this
tissue during peak disease onset that exceeds TfR-mediated
antibody uptake.
We next assessed the potential leakage of endogenous
mouse IgG and serum albumin into brain by western blot anal-
ysis of cortex (Figures 1E and 1F), cerebellum (Figure 1G), and
spinal cord lysates (Figure 1H). We detected significantly
increased levels of extravasated IgG (Figures 1F–1H) and albu-
min (Figures S1A–S1D) in EAE mice compared to naive con-
trols. These EAE-induced increases in plasma proteins were
not accompanied by changes in the tight junction protein clau-
din-5 (Figures S1A–S1C and S1E), suggesting barrier leakage
was not due to degradation of junctional components. We
also observed increased TfR levels in EAE brains and a reduc-
tion in spinal cord (Figure S1F). The increased TfR may
contribute to the slight elevation of TfR bispecific levels de-
tected in EAE brain samples (Figures 1B and 1C), suggesting
greater brain uptake with higher TfR expression. Alternatively,
the slight increases in anti-TfRD/BACE1 in EAE mice may also
be attributed to BBB disruption due to underlying inflammation,
enabling additional passive antibody diffusion, especially in spi-
nal cord (Figure 1D). We also assessed Ab40 concentrations
and found that mice treated with TfR bispecific, either naive
or EAE-induced, had overall decreased Ab40 compared to
those treated with Con IgG or anti-BACE1 (Figures S1G–S1I),
indicating that the mice with higher brain antibody levels dis-
played greater Ab reductions.Lack of Widespread BBB Permeability in Aged PS2-APP
Mice
We first employed a sensitive radiolabeled tracer technique
(Boswell et al., 2012) to explore the overall extent of BBB perme-
ability in the PS2-APP line of transgenic mice, a well-character-
ized preclinical AD model with age-related amyloid pathology
(Grueninger et al., 2010). Molecules of various molecular weights
(3 kDa dextran, 67 kDa albumin, and 150 kDa Con IgG) were ra-
dioiodinated, and their CNS levels were assessed at appropriate
time points after trace-dosing in young (5–6 month, limited
plaque deposition) and aged (15–16 month, extensive plaque
burden) PS2-APP and wild-type (WT) littermate controls. An
additional group of 5-month-old WT mice were LPS-injected
6 hr before trace-dosing to serve as a model with reported
BBB disruption (Takeda et al., 2013). Surprisingly, we did not
detect differences in the levels of any radiotracers between
the PS2-APP mice, young or aged, versus WT (Figures 2A–2D).
Due to the high sensitivity of this assay, this negative finding
strongly suggests a lack of subtle BBB impairments in
the PS2-APP mice, despite significant amyloid pathology at
advanced ages (Grueninger et al., 2010). In addition, only
3 kDa 125I-Dextran had significantly greater brain uptake in
LPS-injected animals (Figure 2A), demonstrating that LPS-
induced peripheral inflammation impairs the BBB only to the
extent of rendering permeability to molecules between 3 kDa
and possibly up to 67 kDa. We also found that brain uptake of
the radioprobe 86Rb+ (rubidium-86, an 86-dalton cation injected
as RbCl that does not cross the intact BBB due to hydrophilicity
and charge), was not significantly different between WT controls
versus young and aged-matched PS2-APP and LPS-injected
mice (Figure 2D). These findings indicate that other properties
of a molecule beyond its molecular weight, such as ionic charge,
may restrict its barrier permeability.
We next dosed PS2-APP mice, aged 10–13 months, with Con
IgG, anti-BACE1, or anti-TfRD/BACE1 at 25mg/kg. At 24 hr post-
dose, cortical levels of Con IgG and anti-BACE1 were similar
between PS2-APP and WT littermates (Figure 2E), suggesting
an absence of barrier leakage or non-specific passage of
i.v.-administered IgG through the BBB. Conversely, anti-TfRD/
BACE1 levels were 4- to 6-fold greater in both genotypes
compared to Con IgG and anti-BACE1, supporting robust TfR-
mediated, active brain uptake. Similar results were obtained
with younger PS2-APP mice (aged 5 months; Figure 2F).
To determine if endogenous mouse IgG and albumin extrava-
sation was also chronically increased in PS2-APP mice, we
probed brain lysates from the aged (Figure 2G) and young (not
shown) cohorts by western blot. We found the levels of mouse
IgG and albumin were similar between WT and PS2-APP mice
(Figures 2H and 2I). Additionally, claudin-5 and TfR were not
altered in the transgenic mice (Figures 2J and 2K). These data,
combined with the radiotracer observations, further indicate
that the BBB of aged, amyloid-laden PS2-APPmice is otherwise
intact and restricts passive brain uptake of antibody.
BBB Integrity Is Intact in Human Tau, ApoE, and SOD1
Mouse Lines
To probe the extent of passive antibody leakage through the
BBB in other widely used models of neurodegenerative disease,Neuron 88, 289–297, October 21, 2015 ª2015 Elsevier Inc. 291
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Figure 3. No Passive BBB Permeability to Injected IgG in hTauP301L, P301S, ApoE Models, and SOD1G93A
(A–F) Transgenic humanmutant (A) TauP301L, (B and C) TauP301S, (D) APOEmouse lines (EKO,APOE knockout; E4KI, APOE4 knockin) and (E and F) SOD1G93A
mice were injected with 25 mg/kg of Con IgG, anti-TfRD/BACE1, or anti-BACE1 and analyzed 24 hr post-dose by ELISA for antibody levels in cortex, cerebellum,
or spinal cord. n = 4–6 per group. Data points are individual mice with mean ± SEM. *p < 0.05, p values are versus WT by Student’s t test. See also Figures S2
and S3.we assessed brain uptake of Con IgG, anti-BACE1, or anti-TfRD/
BACE1 at 24 hr (25 mg/kg dose) in transgenic mice expressing
human TauP301L aged 14–18 months or TauP301S aged 8–
10 months. The tauopathy and neurodegenerative phenotype
in line P301L occurs at later ages (Terwel et al., 2005), while
P301S mice display prominent neurodegeneration by 9 months
(Yoshiyama et al., 2007). Analysis of brain antibody levels from
both P301L- and P301S-dosed mice (Figures 3A and 3B) re-
vealed no differences in passive antibody uptake for Con IgG
and anti-BACE1 compared to WT littermates, with levels at
2–3 nM. We observed a slight but significant reduction in
anti-BACE1 levels in P301L cortex (Figure 3A, p = 0.02). Because
prior studies have reported that the cerebellum BBB is more
leaky (Phares et al., 2006; Hafezi-Moghadam et al., 2007), we
specifically assessed its antibody uptake in P301S mice and
observed no differences from WT (Figure 3C). In both tau lines,Figure 2. No Widespread BBB Disruption in PS2-APP Transgenic Mice
(A–D) Male PS2-APP mice (APP) 5–6 months (m) and 15–16 m and wild-type (W
percent injected dose per gram tissue (%ID/g) in cortex, cerebellum, and brains
kinetics of the various tracers: 1 hr (A), 2 hr (B and C), or 90 s (D). Male mice aged to
6 hr to serve as a positive control for BBB impairment for all tracers. n = 3–7 per
(E–F) PS2-APP mice aged to 10–13 m (E) or 5 m (F) and age-matched WT litterma
and analyzed by ELISA for antibody levels in cortex at 24 hr post-dose. n = 4–5
(G–K) Cortical lysates from aged mice were assessed by western blot for levels
receptor (TfR) (K). Values were normalized to actin and to WT animals. n = 7–11
Data points are individual mice with mean ± SEM.brain uptake of anti-TfRD/BACE1 did not differ between geno-
types, and was significantly greater than Con IgG and anti-
BACE1, confirming that TfR-mediated transcytosis through the
BBB improves brain uptake.
We next assessed BBB antibody permeability in APOE
knockout (EKO) mice and in APOE4 knockin (E4KI) mice at
2–3 months, the age at which BBB impairment was previously
shown (Hafezi-Moghadam et al., 2007; Bell et al., 2012). We
observed that cortical levels of Con IgG and anti-BACE1 in these
lines also did not differ significantly fromWT controls (Figure 3D).
Conversely, levels of anti-TfRD/BACE1were 7- to 10-fold greater
in all three lines. Significantly more TfR bispecific was observed
in EKO and E4KI cortex over WT; however, the effect size of the
difference was negligible. Because we failed to observe signifi-
cant increases in control antibodies in the EKO or E4KI mice,
we used the radiotracer assay to further probe for subtle BBBT) littermates were trace-dosed with radiolabeled molecules and assessed for
tem. Tissues were collected at time points dictated by the serum pharmaco-
5mwere dosed with 10mg/kg of lipopolysaccharide (LPS) and analyzed after
group. ***p < 0.001 versus all groups.
tes were injected with 25 mg/kg of Con IgG, anti-TfRD/BACE1, or anti-BACE1
per group.
of endogenous mouse IgG HC (H), albumin (I), claudin-5 (J), and transferrin-
per group.
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Table 1. Incidence and Size Categorization of Brain Infarcts
Location of Infarct AD % (n = 561) CON % (n = 227)
Any location 36.36 39.64
Cerebral cortex 28.34 31.71
Centrum ovale 2.5 4.41
Deep nuclei 16.57 17.62
Infratenorial 14.61 17.18
Type of Infarct (cortical)
Microinfarct 10.87 17.62
Lacunar 2.31 1.32
Small (1–27 cc) 4.45 6.6
Large (>27 cc) 0.35 0.88disruption in similarly aged EKOmice. Compared toWT controls,
we found that overall, EKO mice did not have significantly more
3 kDa dextran, 10 kDa dextran, Con IgG, RbCl, or labeled RBCs
in the CNS tissues sampled (Figure S2).
We also examined cortex and spinal cord of therapeutically
dosed SOD1G93A mutant mice, a model of familial amyotrophic
lateral sclerosis, at peak onset of motor symptoms (14 weeks).
We observed restricted access of Con IgG and anti-BACE1 in
the transgenic mice and significantly greater uptake of TfR bis-
pecific (Figures 3E and 3F).
All mice were extensively perfused in therapeutic dosing
studies prior to tissue collection to ensure complete removal of
dosed antibody from the vasculature and to prevent overestima-
tion of antibody levels. Plasma antibody concentrations from all
cohorts of therapeutically dosed mice showed no significant dif-
ferences between disease and non-diseased genotypes (data
not shown). These findings, combined with the overall lack of dif-
ferences in brain antibody levels, suggest that the ratio of IgG in
brain to blood is not significantly affected by possible underlying
neuropathology. We further confirmed antibody uptake into
brain parenchyma by assessing Ab40 concentrations. Overall,
animals dosed with TfR bispecific had significantly reduced Ab
levels in cortex compared to Con IgG or anti-BACE1, indicating
efficient antibody uptake in brain (Figures S3A–S3F). We only
analyzed rodent Ab40 in the WT littermates of the PS2-APP
mice (Figures S3A and S3B) because transgene expression of
human Swedish mutant APP precludes BACE1 inhibition (Atwal
et al., 2011). Also, contributions to Ab reductions from the brain
vasculature areminimal due to low expression of BACE1 by brain
endothelial cells (Zhang et al., 2014).
Incidence of Brain Infarcts in Human AD Samples
Resembles Controls
We next examined a large cohort of post-mortem human tissue
from AD patients (n = 561) and age-matched controls (n = 227)
to determine whether there were differences in the number and
size of brain infarcts that may represent evidence of localized
BBB disruption and permeability. Patients with severe cerebro-
vascular disease, vascular dementia, or history of stroke were
excluded from the final dataset (Beach et al., 2015). The total
percentage of brain infarcts was similar between AD and control
samples and remained similar in specific CNS subregions294 Neuron 88, 289–297, October 21, 2015 ª2015 Elsevier Inc.(Table 1). In both AD and controls, most brain infarcts analyzed
were classified as microinfarcts based on size, and no differ-
ences were found in the percentage of samples with various
sized infarcts (Table 1). Infarct volume in all brain areas or
only cortical tissue was also similar in AD and controls (Figures
4A, 4B, and S4A–S4C). AD and control samples were further
categorized based on plaque scores, and no differences in
median infarct volumes between the two groups were identified
(Figure 4C). These findings suggest that contributions to
BBB impairment and leakiness from brain infarcts are not asso-
ciated with disease status and may be a common occurrence
with age.
Cortical TfR Levels Are Not Decreased in AD
We next assessed TfR levels in brain lysates prepared from a
separate cohort of human AD post-mortem tissue. We probed
superior frontal gyrus (SFG) and entorhinal cortex of age-
matched controls, early AD, and confirmed AD samples and de-
tected no differences in TfR levels (Figures 4D–4F). Claudin-5
levels were also not altered between AD and controls (not
shown), while levels of neurofibrillary tau, detected by anti-
PHF-1, confirmed disease status (Figure 4D). We probed brain
lysates from PS2-APP (Figure 2F), Tau P301L (Figures S5A and
S5B), or P301S (Figures S5C and S5D) mice used in our dosing
studies and observed similar TfR levels asWT littermates. Levels
of TfR resembled WT mice in aged human APOE knockin lines
and EKOmice (Figures S5E and S5F) and in diseased SOD1G93A
transgenic mice (Figures S5G and S5H). These data provide ev-
idence that TfR levels in brain are not reduced, thus not limiting
target engagement of TfR-based therapeutics.
DISCUSSION
It is generally believed that the compromised BBB of Alzheimer’s
patients and mouse models accelerates disease onset or pro-
gression and may also increase therapeutic penetrance into
the CNS. Our results show that antibodies do not demonstrate
increased passage into the brain in multiple preclinical models
of AD, and that brain infarct number and size are similar in AD pa-
tients as controls, which opposes the idea of widespread BBB
disruption in AD. We used two quantitative experimental ap-
proaches to measure BBB permeability, a therapeutic anti-
body-dosing paradigm and a sensitive radiotracer assay with
multiple-sized molecular probes. We observed that in the
context of clear BBB disruption in EAE mice, dosed antibodies
showed robust CNS permeability. The amounts of the radio-
tracers and antibodies we detected in brain were very low; how-
ever, the absolute quantifications were above the level of detec-
tion, raising the important and underappreciated point that most
molecules, regardless of molecular weight, cross the healthy
BBB, including therapeutic antibodies (Yu and Watts, 2013).
Thus, the ability to measure baseline levels of compounds in
brain enabled us to compare brain uptake of tracer and thera-
peutically dosed antibody levels between genotypes in our
studies. No differences were observed in levels of endogenous
mouse IgG, albumin, or claudin-5 in the AD transgenic mice
compared to controls, indicating a lack of chronic BBB disrup-
tion. Moreover, levels of TfR were not decreased in AD models
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Figure 4. Brain Infarct Size and TfR Levels in AD Cases Are Similar to Controls
(A and B) Human post-mortem sections were analyzed for infarct volumes (in cc, centimeters cubed) in all brain regions (A), or only in cortical regions (includes
hippocampus) (B). n = 227 controls and 561 AD samples.
(C) Total infarct volumes from AD and control samples were grouped based on plaque scores. Note the y axis is a logarithmic scale. Data points are individual
samples; graphs show medians with interquartile ranges. See also Figure S4.
(D) A separate cohort of post-mortem human brain samples (C, age-matched Controls; E, early AD; A, confirmed AD) were analyzed by western blot for TfR
protein levels in superior frontal gyrus (left) and entorhinal cortex (right). Claudin-5 and PHF1 were probed and actin was the loading control.
(E and F) Quantification of western blots for levels of TfR. n = 8–10 per group. Values were normalized to actin and to controls. Data points are individual samples,
graphs show mean ± SEM.and in samples from AD patients, therefore maintaining the
accessibility of an anti-TfR-based therapeutic.
The variousmethods historically used to assess BBB dysfunc-
tion in AD patients, post-mortem samples, or in mouse models
have led to many disparate findings. Early studies via DCE-
MRI showed no difference between AD patients or age-matched
controls (Schlageter et al., 1987). More recent data have re-
ported decreased blood flow in AD cases (Bateman et al.,
2006; Hanyu et al., 2010) and age-dependent BBB breakdown
in MCI patients, with the cortex remaining largely spared (Mon-
tagne et al., 2015). Our finding that the number and size of
cortical microinfarcts is similar between controls and diseased
samples is aligned with some of these observations and other
histological findings (Del Ser et al., 2005). A caveat of this
approach is the potential underestimation of BBB impairmentby not accounting for non-infarct associated disruption. Other
studies have reported increased incidence of microbleeds
or vascular lesions in AD cases possibly due to comorbid cere-
brovascular vascular dementia or small vessel disease (SVD),
which were not increased in pure AD cases alone (De Reuck,
2012; Toledo et al., 2013). As such, we excluded these cases
in our infarct assessments. Cerebrovascular lesions are a com-
mon observation in most aged control samples (Farrall and
Wardlaw, 2009; Bridges et al., 2014), with old infarcts occurring
in 43% of elderly brains in the Banner Brain Donation Program
from which our dataset and samples were sourced (Beach
et al., 2015).
The transgenic PS2-APP mice utilized in our studies have
extensive parenchymal amyloid and restricted vascular amyloid
on surface meningeal vessels (Grueninger et al., 2010), allowingNeuron 88, 289–297, October 21, 2015 ª2015 Elsevier Inc. 295
us to test if parenchymal plaque alters BBB integrity. Neverthe-
less, studies in mice and humans show a relationship between
cerebrovascular amyloid angiopathy (CAA) and BBBdysfunction
or microhemorrhages (Han et al., 2008; Maier et al., 2014;
Attems, 2005). Thus, additional studies comparing passive brain
uptake of antibodies in APP transgenic mice with and without
CAA are warranted. Recent data have shown that the cerebro-
vascular volume of APP-PS1 mice (no CAA) is unperturbed
with age (Do et al., 2014). Using a chronic i.v. IgG dosing strat-
egy, this group also found that aged 3xTg-AD and E4KI mice
did not have greater IgG accumulation in brain versus controls
(St-Amour et al., 2013; Alata et al., 2015). These studies support
our findings regarding a lack of widespread BBB permeability to
IgG, notably in a different AD model.
Overall, our results demonstrate that the BBB remains intact in
multiple preclinical models of AD. These findings further support
strategies aimed at utilizing TfR-mediated brain uptake as
a viable approach to opening up the CNS to antibody therapeu-
tics in neurodegenerative disease, particularly in Alzheimer’s
disease.
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